Stock MNPR MONOPAR THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Delayed Nasdaq
Other stock markets
 03:02:17 2024-06-14 pm EDT 		5-day change 1st Jan Change
0.94 USD +2.81% Intraday chart for Monopar Therapeutics Inc. +15.91% +176.31%
May. 24 Monopar Therapeutics Names Karthik Radhakrishnan as CFO MT
May. 24 Monopar Therapeutics Inc. Announces CFO Changes CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
JonesTrading Upgrades Monopar Therapeutics to Buy From Hold, Price Target is $2
MT
JonesTrading Downgrades Monopar Therapeutics to Hold From Buy
MT
HC Wainwright Adjusts Monopar Therapeutics' Price Target to $2 From $6, Keeps Buy Rating
MT
Maxim Group Downgrades Monopar Therapeutics to Hold From Buy
MT
Roth MKM Adjusts Price Target on Monopar Therapeutics to $3 From $18, Maintains Buy Rating
MT
EF Hutton Adjusts Price Target on Monopar Therapeutics to $17 From $24, Maintains Buy Rating
MT
Roth Capital Reinstates Monopar Therapeutics at Buy With $18 Price Target
MT
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High
MT
HC Wainwright Adjusts Monopar Therapeutics' Price Target to $6 From $9, Maintains Buy Rating
MT
HC Wainwright Starts Monopar Therapeutics at Buy With $9 Price Target
MT
MONOPAR THERAPEUTICS : Roth Capital Starts Monopar Therapeutics at Buy With $49 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNPR Stock
  4. News Monopar Therapeutics Inc.
  5. Analyst Reco.